Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves diarrhea drug
For adults and teens, the FDA’s decision brings a first-ever treatment for infections caused by the waterborne protozoan that is recognized as widespread in the US. Cryptosporidium is
For adults and teens, the FDA’s decision brings a first-ever treatment for infections caused by the waterborne protozoan that is recognized as widespread in the US. Cryptosporidium is
The study’s findings are important because the onset of damage caused by sickle cell anemia (SCA) complications can occur as early as three months after birth. Starting treatment
Under this agreement, Acologix is granted an exclusive license to develop and commercialize TRK-820 in North America. In Europe, Acologix and Toray will co-develop the compound and Acologix
A completed a special protocol documents the FDA’s agreement that the design and planned analysis of the Study adequately addresses objectives in support of a regulatory submission such
The company said the new product, dubbed PRM R11, includes its Practice Management and Electronic Health Record (EHR) technology. The updated version was developed in response to physician
Premenstrual dysphoric disorder (PMDD) affects approximately 5% of menstruating women according to Metabolon. Symptoms of the disorder include marked depression, anxiety, tension, irritability and moodiness. Considered a mood
The newly granted patent includes broad claims covering therapeutic use of double-stranded RNA expressed from endogenous templates or expression vectors to mediate RNA interference (RNAi). This is the
Under the definitive merger agreement, Pfizer will acquire all outstanding shares of Vicuron common stock at a price of $29.10 per share in cash, for an aggregate equity
GlycoGenesys’ cancer drug candidate GCS-100 has been shown to bind to Galectin-3. Literature demonstrates that Galectin-3 and Bcl-2 are over-expressed in a variety of lymphomas and solid tumor
This recent designation marks the seventh issued patent to cover Indiplon. It will provide Neurocrine with patent exclusivity for Indiplon Polymorph Form III, a novel form of the